Physician profile
Jeffrey G Demain
NPI 1548201395
$228,282.74
in general payments reported to CMS, 2019-2025
34 companies · $68K in 2025
The $68K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $612 · 2021: $4,540 · 2022: $6,158 · 2023: $79K · 2024: $69K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $143K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $31K · Food and Beverage: $6,889 · Consulting Fee: $281 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $142,913.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,542.00 |
| Travel and Lodging | $31,262.00 |
| Food and Beverage | $6,889.16 |
| Consulting Fee | $281.06 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $177,121.69 | 2022-2025 | Ayvakit |
| Sanofi US Services INC. | $39,414.32 | 2025 | |
| Genzyme Corporation | $3,436.10 | 2019-2025 | |
| Phadia US INC. | $1,465.82 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals Lp | $890.81 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Octapharma USA, INC. | $836.14 | 2021 | |
| Glaxosmithkline, LLC. | $687.94 | 2019-2025 | Nucala |
| Genentech USA, INC. | $659.61 | 2020-2024 | Xolair |
| Adma Biomanufacturing LLC | $584.21 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $547.04 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Grifols USA, LLC | $404.70 | 2019-2025 | Gamunex-C, Xembify |
| Amgen INC. | $308.19 | 2022-2025 | Tezspire, Actimmune |
| Pharming Healthcare, INC. | $258.38 | 2020-2024 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $239.43 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $213.51 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $169.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.74 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Pfizer INC. | $101.37 | 2020-2023 | |
| Biogen, INC. | $97.47 | 2023 | Tysabri |
| Csl Behring | $96.64 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.44 | 2020-2023 | Airduo Digihaler |
| Horizon Therapeutics Plc | $60.31 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $53.54 | 2024-2025 | Monoferric |
| Kaleo, INC. | $50.24 | 2020-2021 | |
| Alk-Abello, INC | $48.68 | 2021 | |
| Biocryst US Sales Co., LLC | $46.02 | 2021-2022 | |
| Genentech, INC. | $42.55 | 2019 | |
| Philips North America LLC | $40.60 | 2021-2023 | |
| Optinose US, INC. | $20.52 | 2020 | |
| Tg Therapeutics, INC. | $19.20 | 2024 | |
| Abbvie INC. | $16.84 | 2022 | |
| Mylan Specialty L.P. | $14.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Demain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.